Mass spectrometry method provides first view of stress-induced extracellular protein modification in cells and tissues
Cells that experience stress such as occurring in cancer or inflammatory diseases use various signals to induce a stress response and communicate the stress levels to other cells in the body. One of those signals is a protein modification called ADP-ribosylation. Knowing the precise position and function of ADP-ribosylation on proteins allows the development of new diagnostic and therapeutic tools in various diseases including cancer, infections and neurodegenerative diseases.
First view on extracellular ADP-ribosylation using an advanced mass spectrometry method
This week, researchers from the Department of Molecular Mechanisms of Disease (DMMD) at the University of Zurich (UZH) published in the journal Cell Reports the first description of the extracellular ADP-ribosylomes from cells and tissues, i.e. all proteins carrying the ADP-ribosylation modification and the precise modification site(s) on the proteins.
The researcher focused their analysis on cells of muscle tissue as it has been previously described that an enzyme, called ARTC1, that generates exclusively extracellular ADP-ribosylation is prominently expressed in our skeletal and heart muscle. “Surprisingly, we found that already unstressed cells and tissues comprise a substantial extracellular ADP-ribosylome, which is in contrast to our previous findings on intracellular ADP-ribosylation”, says Dr. Mario Leutert, the first author of the publication, and continues: “Furthermore, it was striking to learn that the ADP-ribosylation sites of muscle and heart are almost exclusively generated by this one enzyme, ARTC1”. These findings had been corroborated in collaboration with a research group from Hamburg led by Prof. Friedrich Koch-Nolte.
“In this study, we also provide evidence for a functional role of extracellular ADP-ribosylation”, says Prof. Michael Hottiger, senior author on the publication and director of the DMMD. Hemopexin is one of the strongest binders of the oxygen-binding molecule hem in the blood and the authors found that ADP-ribosylation of hemopexin reduces its hem-binding capacity. Thus, among many other functions, ADP-ribosylation may regulate hem availability and transport.
Altered ADP-ribosylation status may be a sign of disease
Why is this study important? Prof. Hottiger answers: “With this study we do not just present another method to study proteins and their modification. Together with our previous work and that from other groups in the field, our new results and technical capabilities provide the basis for the future investigations of ADP-ribosylation and its medical implications”. Although ADP-ribosylation is known as a biological process already for 60 years, the functional role of it is still largely unknown, which is due to hitherto lack of appropriate research tools. Still, there is already strong medical evidence that ADP-ribosylation is involved in pathogenic processes and that inhibitors of intracellular ADP-ribosylation, so called PARP inhibitors, are useful in treating cancers such as breast and ovary cancer and may be beneficial in inflammatory conditions.
New diagnostic and therapeutic opportunities
Being now able to study all potential ADP-ribosylated proteins in biopsies or blood at once allows studying the dynamics of ADP-ribosylation at individual protein positions in health and disease. “During the last two years, we have prepared ourselves for this moment and, in parallel, developed the first in kind antibody directed to single-modified, so called mono-ADP-ribosylated proteins” elucidates Prof. Hottiger. “In collaboration with the University Hospital of Zurich, we obtained the first evidence that such antibodies against mono-ADP-ribosylation may be very useful as prognostic tools in certain cancer types”. Prof. Hottiger’s group is now in the process of developing modification- and protein-specific monoclonal antibodies that will allow the determination of the ADP-ribosylation status of a particular protein. In addition, they want to address whether such antibodies would have a therapeutic potential for instance in cancer.
“There is a huge, still undiscovered landscape out there”, concludes Prof. Hottiger, “we still need to learn a lot about ADP-ribosylation, but we are kind of convinced that the medical implications and benefits for patients might be enormous.”
Proteomic Characterization of the Heart and Skeletal Muscle Reveals Widespread Arginine ADP-Ribosylation by the ARTC1 Ectoenzyme.
Mario Leutert, Stephan Menzel, Rickmer Braren, Björn Rissiek, Ann-Katrin Hopp, Kathrin Nowak, Lavinia Bisceglie, Peter Gehrig, Hui Li, Anna Zolkiewska, Friedrich Koch-Nolte, Michael O. Hottiger
Cell Reports 24(7):1916-1929
- The Dutch Research Council (NOW) awarded a 2 year Rubicon grant to Dr. Yannick Kok for his project DNA repair: wrong place, wrong time
- Award Ceremony and Lectures Dr. Ernst Th. Jucker Preis 2019/2020 for Important Contributions to Cancer Research
- The project of the MSRU “Human-Horse Interaction” was awarded the “Prize for Educational Innovations” ”from the Hans-Peter Frey Foundation
- Kaivalya Walavalkar received the prestigious EMBO postdoctoral fellowship
- Scott Finlay PhD and Salim Darwiche PhD awarded first prize for best investor pitch, presenting their marketable product for cartilage repair
- Congratulations to SNSF Prof. Dr. Matthias Altmeyer for being appointed Associate Professor
- Congratulations to Prof.em. Dr. Brigitte von Rechenberg for obtaining ORS 2020 Women’s Leadership Forum Award
- Stephanie Lüthi receives semester price 2019 from VSF
- Prof. Dr. Tuncay Baubec receives ERC Consolidator Grant
- Ramon Pfändler receives semester price from MNF
- Nina Schmolka receives SNF Ambizione Fellowship
- New paper from group M. Altmeyer online in EMBO journal
- Molecular biologist Tuncay Baubec received the renowned Georg Friedrich Götz Award
- Preisgekrönte Nachwuchsforschung
- Verlängerung SNF Förderungsprofessur von Prof. Dr. Tuncay Baubec
- Erfolgsmeldung aus dem Department of Molecular Mechanisms of Disease
- Proteinveränderungen weisen auf Krebs hin
- Tumor Therapy of the Future
- Measuring the Effects of Drugs on Cancer Cells
- Prolongation of SNSF Professorship for Prof. Dr. Matthias Altmeyer
- Raffaella Santoro received the prestigious ERC advanced grant
- Article in UZH Magazin about Matthias Altmeyer on his work "Krebszellen im Burnout"
- Successful and stimulating 3rd Joint Department Colloquium (JDC) of the DMMD
- Important Mechanism of Epigenetic Gene Regulation Identified
- UZH press release on the work of Santoro and Cinelli groups on stem cell pluripotency in Nature Cell Biology
- Professorial appointment process successfully completed
- SNF Prof. Dr. Matthias Altmeyer receives highly prestigious ERC Starting Grant
- Dr. Francisco Verdeguer new group leader at DMMD
- Prof. Dr. Raffaella Santoro elected as new EMBO member
- Dr. Sandra Frommel from the Santoro group receives Jahrespreis of the Vetsuisse Faculty
- Group van Loon publishes on the impact of ribonucleotide incorporation on DNA base excision repair in Nature Communications
- Dr. Barbara van Loon appointed to Associate Professor position at the Norwegian University for Science and Technology
- IVBMB is now Department of Molecular Mechanisms of Disease (DMMD)
- Group Hottiger publishes on identification of genome-wide chromatin ADP-riboslyation in Molecular Cell
- Group Altmeyer publishes on intracellular phase separation in Nature Communications
- IVBMB now also associated with Faculty of Science (MNF)
- Dr. Tuncay Baubec awarded SNF-professorship to be carried out at the IVBMB
- Group Santoro awarded for Cell Stem Cell Cover Page
- Group Santoro publishes major study on predictive marker of prostate cancer recurrence in Nature Genetics
- Dr. Matthias Altmeyer awarded SNF-professorship to be carried out at the IVBMB
- Prof. Michael O. Hottiger new acting director of IVBMB as of 1. February 2014